Effect of Bile Duct Ligation-induced Liver Dysfunction on Methamphetamine Pharmacokinetics and Locomotor Activity in Rats

Authors

  • Michael D Hambuchen Department of Pharmaceutical Science and Research, Marshall University School of Pharmacy, Huntington, WV, USA. Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA
  • Michael D Berquist Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
  • Christy M Simecka Division of Laboratory Animal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
  • Mitchell R McGill Department of Environmental and Occupational Health, Fay W. Boozman College of Public Health, University of Arkansas for Medical Sciences, Little Rock, AR , USA.
  • Melinda G Gunnell Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
  • Howard P Hendrickson Department of Pharmaceutical, Social, and Administrative Sciences, McWhorter School of Pharmacy, Samford University, Birmingham, AL, USA. Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
  • S Michael Owens Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

DOI:

https://doi.org/10.18433/jpps30471

Abstract

Purpose: Methamphetamine (METH) abuse is associated with hepatic dysfunction related comorbidities such as HIV, hepatitis C, and polysubstance abuse with acetaminophen-containing opioid formulations. We aimed to develop a bile duct ligation (BDL)-induced hepatic dysfunction model for studying both METH and experimental treatments for METH abuse in this comorbidity. Methods: Sham or BDL surgery was performed in male Wistar rats on day 0. Liver function was measured throughout the study. On days 7 and 19, serum pharmacokinetics studies were performed with 1 mg/kg subcutaneous (sc) METH. On day 21, this dose was repeated to determine 2 h post-METH brain concentrations. METH-induced open field behaviors were measured every other day (days 12 - 16) with ascending sc doses (0.3 – 3 mg/kg). Results: BDL transiently increased alanine aminotransferase levels and altered liver structure, which resulted in significantly greater METH serum and brain exposure. In the BDL compared to sham group, there was a longer duration of METH-induced locomotor activity (after 1 and 3 mg/kg) and stereotypy (after 3 mg/kg). Conclusions: In rats, liver dysfunction reduced METH clearance, increased brain METH concentrations, and enhanced METH effects on locomotor activity in a dose dependent manner. In addition, this model could be further developed to simulate the associated hepatic dysfunction of key METH abuse comorbidities for preclinical testing of novel pharmacotherapies for effectiveness and/or toxicity in vulnerable populations.

Downloads

Download data is not yet available.

Author Biographies

Michael D Hambuchen, Department of Pharmaceutical Science and Research, Marshall University School of Pharmacy, Huntington, WV, USA. Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA

Department of Pharmaceutical Science and Research, Assistant Professor

Michael D Berquist, Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Department of Pharmacology and Toxicology, Post Doctoral Fellow

Christy M Simecka, Division of Laboratory Animal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Division of Laboratory Animal Medicine, Assistant Professor

Mitchell R McGill, Department of Environmental and Occupational Health, Fay W. Boozman College of Public Health, University of Arkansas for Medical Sciences, Little Rock, AR , USA.

Dept. of Environmental and Occupational Health, Assistant Professor

Melinda G Gunnell, Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Department of Pharmacology and Toxicology, Research Program Manager

Howard P Hendrickson, Department of Pharmaceutical, Social, and Administrative Sciences, McWhorter School of Pharmacy, Samford University, Birmingham, AL, USA. Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Department of Pharmaceutical, Social, and Administrative Sciences, Professor and Department Chair

S Michael Owens, Department of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Department of Pharmacology and Toxicology, Professor

References

DEA. National Drug Threat Assessment. In: Administration US DoJ and DEA, editor. 2018. Available from: https://www.dea.gov/documents/2018/10/02/2018-national-drug-threat-assessment-ndta

Cook R, Quinn B, Heinzerling K, Shoptaw S. Dropout in clinical trials of pharmacological treatment for methamphetamine dependence: the role of initial abstinence. Addiction. 2017;112(6):1077-85.

Owens SM, Atchley WT, Hambuchen MD, Peterson EC, Gentry WB. Monoclonal antibodies as pharmacokinetic antagonists for the treatment of (+)-methamphetamine addiction. CNS Neurol Disord Drug Targets. 2011;10(8):892-8.

Beardsley PM, Hauser KF. Glial modulators as potential treatments of psychostimulant abuse. Adv Pharmacol. 2014;69:1-69.

Stevens MW, Henry RL, Owens SM, Schutz R, Gentry WB. First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers. MAbs. 2014;6(6):1649-56.

Worley MJ, Heinzerling KG, Roche DJ, Shoptaw S. Ibudilast attenuates subjective effects of methamphetamine in a placebo-controlled inpatient study. Drug Alcohol Depend. 2016;162:245-50.

Hartzler B, Dombrowski JC, Crane HM, Eron JJ, Geng EH, Christopher Mathews W, et al. Prevalence and Predictors of Substance Use Disorders Among HIV Care Enrollees in the United States. AIDS Behav. 2017;21(4):1138-48.

Gonzales R, Marinelli-Casey P, Shoptaw S, Ang A, Rawson RA. Hepatitis C virus infection among methamphetamine-dependent individuals in outpatient treatment. J Subst Abuse Treat. 2006;31(2):195-202.

Havens JR, Stoops WW, Leukefeld CG, Garrity TF, Carlson RG, Falck R, et al. Prescription opiate misuse among rural stimulant users in a multistate community-based study. Am J Drug Alcohol Abuse. 2009;35(1):18-23.

Te HS. Cholestasis in HIV-infected patients. Clin Liver Dis. 2004;8(1):213-28, viii-ix.

Anadol E, Lust K, Boesecke C, Schwarze-Zander C, Mohr R, Wasmuth JC, et al. Exposure to previous cART is associated with significant liver fibrosis and cirrhosis in human immunodeficiency virus-infected patients. PLoS One. 2018;13(1):e0191118.

Bosh KA, Coyle JR, Hansen V, Kim EM, Speers S, Comer M, et al. HIV and viral hepatitis coinfection analysis using surveillance data from 15 US states and two cities. Epidemiol Infect. 2018;146(7):920-30.

Liu X, Chang L, Vigorito M, Kass M, Li H, Chang SL. Methamphetamine-induced behavioral sensitization is enhanced in the HIV-1 transgenic rat. J Neuroimmune Pharmacol. 2009;4(3):309-16.

Kass MD, Liu X, Vigorito M, Chang L, Chang SL. Methamphetamine-induced behavioral and physiological effects in adolescent and adult HIV-1 transgenic rats. J Neuroimmune Pharmacol. 2010;5(4):566-73.

Kesby JP, Najera JA, Romoli B, Fang Y, Basova L, Birmingham A, et al. HIV-1 TAT protein enhances sensitization to methamphetamine by affecting dopaminergic function. Brain Behav Immun. 2017;65:210-21.

Soontornniyomkij V, Kesby JP, Morgan EE, Bischoff-Grethe A, Minassian A, Brown GG, et al. Effects of HIV and Methamphetamine on Brain and Behavior: Evidence from Human Studies and Animal Models. J Neuroimmune Pharmacol. 2016;11(3):495-510.

Agarwal N, Iyer D, Gabbi C, Saha P, Patel SG, Mo Q, et al. HIV-1 viral protein R (Vpr) induces fatty liver in mice via LXRalpha and PPARalpha dysregulation: implications for HIV-specific pathogenesis of NAFLD. Sci Rep. 2017;7(1):13362.

Ghoneim RH, Piquette-Miller M. Endotoxin-Mediated Downregulation of Hepatic Drug Transporters in HIV-1 Transgenic Rats. Drug Metab Dispos. 2016;44(5):709-19.

Halpin LE, Gunning WT, Yamamoto BK. Methamphetamine causes acute hyperthermia-dependent liver damage. Pharmacol Res Perspect. 2013;1(1):e00008.

Halpin LE, Yamamoto BK. Peripheral ammonia as a mediator of methamphetamine neurotoxicity. J Neurosci. 2012;32(38):13155-63.

Northrop NA, Halpin LE, Yamamoto BK. Peripheral ammonia and blood brain barrier structure and function after methamphetamine. Neuropharmacology. 2016;107:18-26.

Tarcin O, Basaranoglu M, Tahan V, Tahan G, Sucullu I, Yilmaz N, et al. Time course of collagen peak in bile duct-ligated rats. BMC Gastroenterol. 2011;11:45.

Basseches PJ, DiGregorio GJ. Pharmacokinetics of procainamide in rats with extrahepatic biliary obstruction. J Pharm Sci. 1982;71(11):1256-9.

Esmaeili Z, Mohammadi S, Nezami A, Rouini MR, Ardakani YH, Lavasani H, et al. A disposition kinetic study of Tramadol in bile duct ligated rats in perfused rat liver model. Biomed Pharmacother. 2017;91:251-6.

Han SS, Kim KY, Ham SH, Sohn DH, Kim JB. Pharmacokinetics of theophylline: effects of hepatic fibrosis in rats induced bile duct ligation. Biol Pharm Bull. 1995;18(3):470-3.

Yang Y, Chen B, Chen Y, Zu B, Yi B, Lu K. A comparison of two common bile duct ligation methods to establish hepatopulmonary syndrome animal models. Lab Anim. 2015;49(1):71-9.

Byrnes-Blake KA, Laurenzana EM, Carroll FI, Abraham P, Gentry WB, Landes RD, et al. Pharmacodynamic mechanisms of monoclonal antibody-based antagonism of (+)-methamphetamine in rats. Eur J Pharmacol. 2003;461(2-3):119-28.

Gentry WB, Ghafoor AU, Wessinger WD, Laurenzana EM, Hendrickson HP, Owens SM. (+)-Methamphetamine-induced spontaneous behavior in rats depends on route of (+)METH administration. Pharmacol Biochem Behav. 2004;79(4):751-60.

Hambuchen MD, Hendrickson HP, Owens SM. Chiral determination of 3,4-methylenedioxypyrovalerone enantiomers in rat serum. Anal Methods. 2017;9(4):609-17.

Hambuchen MD, Carroll FI, Ruedi-Bettschen D, Hendrickson HP, Hennings LJ, Blough BE, et al. Combining Active Immunization with Monoclonal Antibody Therapy To Facilitate Early Initiation of a Long-Acting Anti-Methamphetamine Antibody Response. J Med Chem. 2015;58(11):4665-77.

Lam FC, Hung CT, Perrier DG. Estimation of variance for harmonic mean half-lives. J Pharm Sci. 1985;74(2):229-31.

Harnoss JC, Heidecke CD, Vollmar B, Eipel C. In vivo imaging of bile accumulation and biliary infarction after common bile duct ligation in rats. Eur Surg Res. 2011;47(4):240-7.

Terzic D, Brmbolic B, Singer D, Dupanovic B, Korac M, Selemovic D, et al. Liver enlargement associated with opportunistic infections in patients with human immunodeficiency virus infection. J Gastrointestin Liver Dis. 2008;17(4):401-4.

Iwakiri Y. Pathophysiology of portal hypertension. Clin Liver Dis. 2014;18(2):281-91.

Milesi-Halle A, Hendrickson HP, Laurenzana EM, Gentry WB, Owens SM. Sex- and dose-dependency in the pharmacokinetics and pharmacodynamics of (+)-methamphetamine and its metabolite (+)-amphetamine in rats. Toxicol Appl Pharmacol. 2005;209(3):203-13.

Hambuchen MD, Ruedi-Bettschen D, Gunnell MG, Hendrickson H, Owens SM. Chronic treatment of (+)-methamphetamine-induced locomotor effects in rats using one or a combination of two high affinity anti-methamphetamine monoclonal antibodies. Hum Vaccin Immunother. 2016;12(9):2240-8.

Schiorring E. Amphetamine induced selective stimulation of certain behaviour items with concurrent inhibition of others in an open-field test with rats. Behaviour. 1971;39(1):1-17.

Kitaichi K, Morishita Y, Doi Y, Ueyama J, Matsushima M, Zhao YL, et al. Increased plasma concentration and brain penetration of methamphetamine in behaviorally sensitized rats. Eur J Pharmacol. 2003;464(1):39-48.

Miller ML, Moreno AY, Aarde SM, Creehan KM, Vandewater SA, Vaillancourt BD, et al. A methamphetamine vaccine attenuates methamphetamine-induced disruptions in thermoregulation and activity in rats. Biol Psychiatry. 2013;73(8):721-8.

Hambuchen MD, Ruedi-Bettschen D, Williams DK, Hendrickson H, Owens SM. Treatment of rats with an anti-(+)-methamphetamine monoclonal antibody shortens the duration of action of repeated (+)-methamphetamine challenges over a one month period. Vaccine. 2014;32(47):6213-9.

Quinn M, McMillin M, Galindo C, Frampton G, Pae HY, DeMorrow S. Bile acids permeabilize the blood brain barrier after bile duct ligation in rats via Rac1-dependent mechanisms. Dig Liver Dis. 2014;46(6):527-34.

Schindler CW, Bross JG, Thorndike EB. Gender differences in the behavioral effects of methamphetamine. Eur J Pharmacol. 2002;442(3):231-5.

Milesi-Halle A, McMillan DE, Laurenzana EM, Byrnes-Blake KA, Owens SM. Sex differences in (+)-amphetamine- and (+)-methamphetamine-induced behavioral response in male and female Sprague-Dawley rats. Pharmacol Biochem Behav. 2007;86(1):140-9.

Milesi-Halle A, Hambuchen MD, McMillan DE, Michael Owens S. The pharmacokinetics of methamphetamine self-administration in male and female rats. Drug Alcohol Depend. 2015;150:164-9.

Kogachi S, Chang L, Alicata D, Cunningham E, Ernst T. Sex differences in impulsivity and brain morphometry in methamphetamine users. Brain Struct Funct. 2017;222(1):215-27.

Downloads

Published

2019-07-16

How to Cite

Hambuchen, M. D., Berquist, M. D., Simecka, C. M., McGill, M. R., Gunnell, M. G., Hendrickson, H. P., & Owens, S. M. (2019). Effect of Bile Duct Ligation-induced Liver Dysfunction on Methamphetamine Pharmacokinetics and Locomotor Activity in Rats. Journal of Pharmacy & Pharmaceutical Sciences, 22(1), 301–312. https://doi.org/10.18433/jpps30471

Issue

Vol. 22 (2019): Pages 131 - 364

Section

Pharmaceutical Sciences; Original Research Articles

License

This is an open access journal with free of charge non-commercial download. At the time of submission, authors will be asked to transfer the copyright to the accepted article to the Journal of Pharmacy and Pharmaceutical Sciences. The author may purchase the copyright for $500 upon which he/she will have the exclusive copyright to the article. Nevertheless, acceptance of a manuscript for publication in the Journal is with the authors' approval of the terms and conditions of the Creative Commons copyright license Creative Common license (Attribution-ShareAlike) License for non-commercial uses.

CLOCKSS system has permission to collect, preserve, and serve this Archival Unit.